Use of thiazolidinedione and cancer risk in Type 2 diabetes: The Hong Kong diabetes registry

被引：10

作者：

Yang, Xilin ^{[1
,2
]}

So, Wing-Yee ^{[2
,3
,4
]}

Ma, Ronald C. W. ^{[2
,3
,4
]}

Yu, Linda W. L. ^{[5
]}

Kong, Alice P. S. ^{[2
,3
,4
]}

Lee, Heung Man ^{[2
,3
,4
]}

Xu, Gang ^{[2
,3
,4
]}

Ozaki, Risa ^{[2
,3
]}

Ko, Gary T. C. ^{[2
,3
]}

Chan, Juliana C. N. ^{[2
,3
,4
]}

机构：

[1] Tianjin Med Univ, Coll Publ Hlth, Dept Epidemiol, Tianjin 300070, Peoples R China

[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China

[3] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Hong Kong, Peoples R China

[4] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China

[5] Hosp Author Headquarter, Hong Kong, Hong Kong, Peoples R China

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2012年 / 97卷 / 01期

关键词：

Thiazolidinediones; Cancer; Type; 2; diabetes; ROSIGLITAZONE; HYPERGLYCEMIA; PIOGLITAZONE; ASSOCIATIONS;

D O I：

10.1016/j.diabres.2012.03.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We examined possible anticancer effects of thiazolidinediones (TZDs) in 6074 Chinese with Type 2 diabetes free of cancer at enrolment. During a median follow-up of 4.93 years, 270 patients developed cancer. Use of TZDs was associated with reduced risk of cancer in a dose-response manner in multivariable analysis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E11 / E15

页数：5

共 50 条

[41] Pioglitazone and oral cancer risk in patients with type 2 diabetes
Tseng, Chin-Hsiao
ORAL ONCOLOGY, 2014, 50 (02) : 98 - 103
[42] Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes
Tseng, Chin-Hsiao
ANNALS OF MEDICINE, 2013, 45 (08) : 539 - 544
[43] Serum adiponectin predicts fracture risk in individuals with type 2 diabetes: the Fukuoka Diabetes Registry
Komorita, Yuji
Iwase, Masanori
Fujii, Hiroki
Ohkuma, Toshiaki
Ide, Hitoshi
Jodai-Kitamura, Tamaki
Sumi, Akiko
Yoshinari, Masahito
Nakamura, Udai
Kang, Dongchon
Kitazono, Takanari
DIABETOLOGIA, 2017, 60 (10) : 1922 - 1930
[44] High risk for cardiovascular disease in Chinese type 2 diabetic patients with major depression-A 7-year prospective analysis of the Hong Kong Diabetes Registry
Ting, Rose Z. W.
Lau, Eric S. H.
Ozaki, Risa
Lau, Winnie W. Y.
Kong, Alice P. S.
Luk, Andrea O. Y.
Chow, Chun-Chung
Ma, Ronald C. W.
Wing, Yun-Kwok
Chan, Juliana C. N.
So, Wing-yee
JOURNAL OF AFFECTIVE DISORDERS, 2013, 149 (1-3) : 129 - 135
[45] The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, Hanford
Rivera, Kathya
Lomonaco, Romina
Cusi, Kenneth
CURRENT DIABETES REPORTS, 2013, 13 (03) : 329 - 341
[46] The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Hanford Yau
Kathya Rivera
Romina Lomonaco
Kenneth Cusi
Current Diabetes Reports, 2013, 13 : 329 - 341
[47] A prospective study of type 2 diabetes, metformin use, and risk of breast cancer
Park, Y-M M.
Bookwalter, D. B.
O'Brien, K. M.
Jackson, C. L.
Weinberg, C. R.
Sandler, D. P.
ANNALS OF ONCOLOGY, 2021, 32 (03) : 351 - 359
[48] Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus
Koffarnus, Robin L.
Wargo, Kurt A.
Phillippe, Haley M.
ANNALS OF PHARMACOTHERAPY, 2013, 47 (06) : 877 - 885
[49] Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Bae, Jaehyun
Park, Taegyun
Kim, Hyeyoung
Lee, Minyoung
Cha, Bong-Soo
DIABETES & METABOLISM JOURNAL, 2021, 45 (03) : 326 - 336
[50] The risk of developing type 2 diabetes after gestational diabetes: A registry study from Finland
Peramaki, Roosa
Gissler, Mika
Ollila, Meri-Maija
Hukkanen, Janne
Vaarasmaki, Marja
Uotila, Jukka
Metso, Saara
Hakkarainen, Heidi
Rintamaki, Reeta
Kaaja, Risto
Immonena, Heidi
DIABETES EPIDEMIOLOGY AND MANAGEMENT, 2023, 10

← 1 2 3 4 5 →